Abrilada (Adalimumab-afzb) for Psoriasis

Overview

Abrilada is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat plaque psoriasis and psoriatic arthritis, as well as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, adult Crohn’s disease, and ulcerative colitis. Abrilada is also known by its drug name, Adalimumab-afzb.

Abrilada is a tumor necrosis factor (TNF) blocker. It is believed to work by suppressing the inflammatory immune response brought about by the cell-signaling protein TNF, thereby reducing symptoms of psoriasis, psoriatic arthritis, and some other autoimmune diseases. Abrilada is biologically similar to the FDA-approved drug Humira (Adalimumab).

How do I take it?

Abrilada is taken as a subcutaneous injection every other week.

Side effects

The FDA-approved label for Abrilada lists common side effects including infections (such as upper respiratory or sinus infections), injection site reactions, headache, and rash.

Rare but serious side effects can include advanced infections, such as tuberculosis and bacterial sepsis, as well as lymphoma and other malignancies in young adults and children.

For more details about this treatment, visit:

Abrilada — Pfizer

Information on Tumor Necrosis Factor (TNF) Blockers — U.S. Food and Drug Administration